University of Texas MD Anderson Cancer Center
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of Texas MD Anderson Cancer Center
Plus agreements involving Hansoh/GHDDI, BriaCell/UMBC, Novartis/UC Berkeley, NeoPhore/Memorial Sloan Kettering, GEn1E/UM-Baltimore, ValoTx/University of Helsinki and Sosei/Cancer Research UK.
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
- Academic and Research Institutions